The phase III multinational endTB trial confirmed the noninferiority of three all-oral regimens for treating rifampin-resistant tuberculosis, improving prospects for effective, simple, all-oral treatment for adults and children with this disease. The trial involved 754 participants and compared standard therapy with experimental regimens consisting of multiple drugs. The oral regimens offer a potential option for shortening treatment duration and improving adherence for patients residing in high-burden tuberculosis settings.